Geminus.AI Secures $750,000.00 Seed Investment from Sentiero Ventures

Sentiero Ventures, a Dallas-based venture capital fund, has made a $750,000.00 seed investment in Geminus.AI, the physics-informed AI modeling platform that solves the challenges of conventional AI: inaccuracy, heavy data requirements, long training times, and difficulty updating.

"We believe that AI in its current form will struggle to deliver ROI in complex systems that cannot tolerate insufficient accuracy and dynamically change over time. For example, our models can power digital twins that predict the behavior of highly complex processes, and enable increased productivity, at a level that does not yet exist today," said Greg Fallon, CEO of

The investments an organization makes in modeling technology can be staggering and the risks associated with generating expensive, ineffective models are high. Geminus instantly improves ROI with fast, effective models and digital twins that lower costs, while reducing the risks of bad decision-making. The Geminus platform uses novel, first-principles AI computing to translate constraints of the physical world inside resilient digital models.

"We believe that Geminus has a truly novel approach to creating digital twins of complex processes," notes David Evans, Managing Partner of Sentiero Ventures. "In addition, they've assembled a truly world class, experienced team to bring the platform to market."

Geminus will use proceeds from the funding to accelerate its customer acquisition and scale up their go-to-market team. In addition, the funding will help expand on key channel partnerships to accelerate growth.

The $5.9M financing included participation from existing investors, strategic partners, and management.


Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.